(Q37851516)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Riociguat for the treatment of pulmonary hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

main subject

arterial hypertension

0 references

riociguat

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Norbert Weissmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Friedrich Grimminger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Ardeschir Ghofrani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Wiebke Janssen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Johannes-Peter Stasch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

11 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

567-576

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

Updated clinical classification of pulmonary hypertension.

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Molecular pathogenesis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Hypoxic activation of adventitial fibroblasts: role in vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Pulmonary hypertension and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Pulmonary hypertension: current diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Biochemistry of soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Guanylate cyclase and the .NO/cGMP signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Regulation of nitric oxide-sensitive guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

NO-independent, haem-dependent soluble guanylate cyclase stimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

NO-independent regulatory site on soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565048

10.1517/13543784.2011.565048

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391889%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference